維峯電子(301328.SZ):維康汽車已完成產品開發及部分客户導入,進入小批量量產階段
格隆匯5月30日丨維峯電子(301328.SZ)於投資者互動平台表示,維康汽車已完成產品開發及部分客户導入,進入小批量量產階段。公司基於維康汽車自身的發展現狀及需要,加之對新能源汽車智能化、電動化趨勢下對車載高頻高速連接器的市場規模需求增長的信心,公司對維康汽車進行增資並增加控股比例。維康汽車的核心產品為Fakra、miniFakra、以太網等高頻高速連接器,可應用於智能駕駛和車路雲系統組件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.